Newmarket Strategy, an independent life sciences consultancy and market access specialist, has secured a growth capital investment from Baird Capital’s Global Private Equity Fund. The investment will support the company’s continued growth in pharmaceutical services and healthcare advisory.
Founded in 2021, Newmarket applies deep market access, commercial and policy expertise to the health and life sciences sector. The team works with clients to assess market opportunities, secure reimbursement from national and local payors, and drive the uptake of health innovations. Clients include global pharmaceuticals and biotech, med-tech, diagnostics, digital health, private equity and healthcare services providers.
“We are thrilled to partner with Baird Capital for Newmarket’s next stage of growth,” said Ed Jones, Chief Executive at Newmarket Strategy. “We were hugely impressed by Baird Capital’s team and partnership style, by their proven expertise and by the commitment they show to our sector. We are immensely proud of the hard work by all our team to date, and of the continued faith shown by our valued clients.”
“We are excited to support Newmarket’s ambition to be the leader in its field,” said Michael Holgate, Partner with Baird Capital’s Global Private Equity team. “The team brings a high level of expertise, and the services they provide address a critical need across the clients they serve. This investment in Newmarket follows a number of previous investments that we have made in the Pharma Services segment including Campbell Alliance, Prescient and Blue Matter. We look forward to working with Ed and the team to grow Newmarket over the upcoming years.”
Baird Capital was advised by Squire Patton Boggs (Legal), Clearwater (Corporate Finance), T4 (Voice of Customer), Candesic (Commercial Diligence), BDO (Financial & Tax), New Street Consulting (Management), and WTW (Insurance); Newmarket was advised by JMW (Legal) and MHA (Corporate Advisory).
